Genentech, a member of Roche, announced topline results of the Phase III CENTERSTONE study of Xofluza, an antiviral, showing a reduction in the transmission of influenza viruses. The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus. Xofluza was well tolerated with no new safety signals identified. CENTERSTONE is the first global Phase III study to show a transmission reduction benefit with an antiviral used in the treatment of a respiratory viral illness. This new data may add to the benefits of Xofluza which is currently approved for treating symptoms and preventing infection following virus exposure. The topline results will be presented at the 2024 OPTIONS XII for the Control of Influenza Congress.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
- FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
- FDA approves Genentech’s Ocrevus Zunovo
- Boeing factory workers strike halts 737 MAX production: Morning Buzz
- Roche downgraded to Sell from Hold at Deutsche Bank